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Abstract
Various experimental studies indicate potential involvement of bone marrow (BM)-derived stem cells (SCs) in malignancy development and pro-
gression. In this study, we comprehensively analysed systemic trafficking of various populations of BM-derived SCs (BMSCs), i.e., mesenchy-
mal, haematopoietic, endothelial stem/progenitor cells (MSCs, HSCs, EPCs respectively), and of recently discovered population of very small
embryonic/epiblast-like SCs (VSELs) in pancreatic cancer patients. Circulating CD133+/Lin/CD45/CD34+ cells enriched for HSCs, CD105+/
STRO-1+/CD45 cells enriched for MSCs, CD34+/KDR+/CD31+/CD45 cells enriched for EPCs and small CXCR4+CD34+CD133+ subsets of
LinCD45 cells that correspond to VSELs were enumerated and sorted from blood samples derived from 29 patients with pancreatic cancer,
and 19 healthy controls. In addition, plasma levels of stromal-derived factor-1 (SDF-1), growth/inhibitory factors and sphingosine-1-phosphate
(S1P; chemoattractants for SCs), as well as, of complement cascade (CC) molecules (C3a, C5a and C5b-9/membrane attack complex – MAC)
were measured. Higher numbers of circulating VSELs and MSCs were detected in pancreatic cancer patients (P < 0.05 and 0.01 respectively).
This trafficking of BMSCs was associated with significantly elevated C5a (P < 0.05) and C5b-9/MAC (P < 0.005) levels together with S1P con-
centrations detected in plasma of cancer patients, and seemed to be executed in a SDF-1 independent manner. In conclusion, we demonstrated
that in patients with pancreatic cancer, intensified peripheral trafficking of selected populations of BMSCs occurs. This phenomenon seems to
correlate with systemic activation of the CC, hepatocyte growth factor and S1P levels. In contrast to previous studies, we demonstrate herein
that systemic SDF-1 levels do not seem to be linked with increased mobilization of stem cells in patients with pancreatic cancer.
Keywords: bone marrow-derived stem cells complement cascade growth/inhibitory factors pancreatic cancer
SDF-1 S1P
Introduction
Pancreatic cancer constantly remains a leading cause of mortality
among western societies. This grieving tendency continues mainly
because of constant clinical difficulties in its early detection, as well
as, limited treatment opportunities for advanced disease, presented
by vast majority of affected individuals upon diagnosis. In addition,
exact molecular mechanisms responsible for pancreatic malignancy
development seem to be poorly understood [1, 2].
Within the last decades the ‘cancer stem cell’ hypothesis has been
proposed, which postulates a novel concept of hierarchical organiza-
tion of cells, in which ‘primitive’ cancer-initiating SCs were believed to
be responsible for development and growth of tumours, and promotion
of their metastatic spread (reviewed in [3]). So far, results derived from
analysis of experimental animal models or cell lines of breast or colo-
rectal malignancies delivered some evidence supporting this concept
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[4, 5]. Nevertheless, a breakthrough discovery was made by Houghton
and colleagues [6], who demonstrated that gastric cancer may origi-
nate from SCs derived from the BM. As was further confirmed in exper-
imental animals, BMSCs may participate in both – the development
and progression of gastrointestinal tumours [6–8]. Unfortunately,
these observations have never been verified in clinical setting.
In the BM environment, several populations of SCs may be found,
and these include (i) HSCs responsible for repopulation of blood cells,
(ii) MSCs participating in regeneration of various organs (mainly
derived from mesenchyme), and/or (iii) EPCs that may contribute to
neovascularization. However, recently a novel population of SCs has
been identified in murine and human BM, that is a population of VSELs
[9,10]. From the morphological point of view, this unique group of
very small (4–7 lm) LinCD45CD133+ SCs resembles developmen-
tally ‘primitive’ cells, and expresses genetic markers characteristic for
embryonic/pluripotent SCs, such as Oct-4, Nanog, SSEA-4 and Rex1.
In addition, VSELs remain quiescent in dormant state in tissues due to
specific reprogramming of a somatic genomic imprinting, and in com-
parison to other populations of SCs possess around 10–200 times
much higher expression of genes necessary for trans-differentiation
into tissues/organs originating from all three germ layers (including GI
tract) [9–11]. Therefore, their powerful molecular potential and char-
acteristics makes them an ideal potential candidate population of SCs
that may be responsible for initiation of malignancy development in
human beings and/or supporting growing tumour by supplying cells
involved in its neovascularization and stromalization [12].
Taking all these facts into consideration, in this study, we wanted
to translate these previous observations, and comprehensively ana-
lyse whether intensified peripheral trafficking of various populations
of BMSCs is observed in patients with pancreatic cancer. In addition,
we decided to examine (i) systemic levels of an established SCs
chemoattractant – stromal-derived factor-1 (SDF-1), (ii) a wide panel
of growth/inhibitory factors [vascular/endothelial, epidermal, hepato-
cyte, insulin-like growth factors (VEGF, EGF, HGF and IGF respec-
tively) and leukaemia inhibitory factor-LIF], that could be responsible
for observed alterations in peripheral circulation of BMSCs, as well
as, (iii) whether systemic trafficking of BMSCs in pancreatic cancer
patients is associated with plasma levels of molecules released during
activation of CC (C3a, C5a and C5b-9/MAC) and sphingosine-1-phos-
phate (S1P), as proposed in the recent studies [13, 14]. Our hypothe-
sis was that in patients with pancreatic cancer, intensified systemic
trafficking of various BMSCs populations (mainly VSELs and MSCs)
occurs in peripheral blood (PB), and is associated with increased lev-
els of immunomodulatory compounds, such as complement-derived
molecules and/or S1P.
Materials and methods
Patients and blood samples
A total of 29 individuals in a general good state with freshly diagnosed
pancreatic cancer, and 19 healthy controls were included in the study.
All patients recruited were hospitalized in the Department of Gastroenter-
ology of the Pomeranian Medical University in Szczecin. Final diagnosis
of the disease was based on analysis of biopsy specimen, which in all
cases revealed adenocarcinoma type of pancreatic malignancy. To estab-
lish staging of the disease, all patients underwent ultrasonography, com-
puted tomography and/or endoscopic ultrasonography and chest x-ray
examinations. Among the included individuals, six patients were qualified
for surgical removal of the pancreatic tumour, eight patients presented
inoperable locally advanced disease and 15 had distal metastases. Upon
inclusion to the study, none of the patients was on chemotherapy treat-
ment, received any cytotoxic agents/drugs within the last 12 months
before the study, nor presented signs of an active infectious disease.
General characteristics of the individuals enrolled in the study, together
with statistical comparison of these features between examined groups,
are presented in Table 1.
Peripheral blood samples (8–10 ml) were collected from all included
individuals. The absolute numbers of leucocytes and lymphocytes in PB
were determined at the same time with an automatic cell counter (SYS-
MEX XT-2000i; Sysmex Corporation, Kobe, Japan). Blood samples were
centrifuged to obtain whole cell pellet and plasma fractions. Subsequently,
plasma samples were frozen and stored at 80°C until further assess-
Table 1 General characteristic of surgical procedure and of




Age (years) 58  11 61  7
Gender (M-men/W-women) (10-M/9-W) (19-M/10-W)
BMI (kg/m2) 25.12  3.43 26.18  4.56
RBC (91012 cells/l) 4.67  0.73 4.38  0.84
Hb (g/dl) 14.26  1.57 12.56  2.63
Platelets count (9109 cells/l) 209  47 253  102
WBC count (9109 cells/l) 8.01  1.91 9.16  4.09
CRP (mg/l) 3.07  2.88 8.57  2.14*
CA19.9 (U/ml) 17.81  4.15 194.11  73.01*
Subjective pain intensity (n [%])
None 17 [89.5] 15 [51.7]
Delicate 2 [10.5] 6 [20.7]
Moderate 0 [0] 4 [13.8]
Intensive 0 [0] 4 [13.8]
General feeling (n [%])
Good 19 [100] 15 [51.7]
Poor 0 [0] 10 [34.5]
Terrible/very weak 0 [0] 4 [13.8]
BMI: body mass index; RBC: red blood cells; Hb: haemoglobin; WBC:
white blood cells; CRP: C-reactive protein.
*P < 0.01 (versus control group).
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ment of selected growth/inhibitory factors and immunomodulatory mole-
cules. The population of PB-derived leucocytes was obtained from
collected cell pellets after lysis of red blood cells with ammonium chlo-
ride-based lysing solution (BD Pharm Lyse Buffer; BD Biosciences
Pharmingen, San Diego, CA, USA). Purified whole leucocyte factions
were further used for staining and flow cytometric analysis towards
stem/progenitor cell identification as described below. PB samples uti-
lized for identification and isolation of SC populations were processed up
to 12 hrs after blood draw from individual patients. The same processing
and cell isolation procedures were applied to PB samples harvested from
healthy and cancer individuals.
Flow cytometry analysis of circulating
populations of BMSCs
Flow cytometry analysis was performed according to the procedures
previously described [15, 16]. Briefly, circulating VSELs (FSClow/SSClow/
CD45/Lin/CD133+ and FSClow/SSClow/CD45/Lin/CD34+ cells) and
HSCs (CD45+/Lin/CD133+ and CD45+/Lin/CD34+ cells) were identified
following immunostaining of the whole PB-derived nucleated cell frac-
tion against haematopoietic lineage markers (Lin), CD45 antigen,
CD133, or CD34. Antibodies for Lin markers included the following fluo-
rescein isothiocyanate (FITC)-conjugated murine anti-human antibodies
directed against following antigens: CD2, CD3, CD14, CD66b, CD24,
CD56, CD16, CD19 and CD235a. EPCs (CD45/CD31+/CD133+ and
CD45/CD31+/CD34+/KDR+ cells) were stained with fluorescent-labelled
antibodies for CD45, CD31, CD133, CD34 and KDR (also known as
VEGFR2), while the labelling of MSCs employed antibodies for such
antigens as CD45, CD105 and Stro-1. Appropriate sets of isotype con-
trol antibodies were used for each staining and such negative control
samples were used to set up gating strategy for identification of all indi-
cated SC populations (VSELs, HSCs, EPCs and MSCs).
In addition, a single-cell suspension was stained for lineage markers
(CD56, CD235a, CD3, CD66b, CD24, CD19, CD14, CD16 and CD2) con-
jugated with fluorescein isothiocyanate, CD45 conjugated with PE and
CXCR4 conjugated with APC. Samples were incubated with antibodies
in PBS containing 2% foetal bovine serum (FBS; Life Technologies,
Grand Island, NY, USA) for 30 min. on ice and then were washed and
fixed with 4% paraformaldehyde solution for 20 min. Fixed cells were
subsequently stained with Hoechst 33342 (2 lg/ml, Sigma-Aldrich, St.
Louis, MO, USA) to visualize nucleated objects and exclude debris from
subsequent analysis with an LSR II flow cytometer (Becton Dickinson,
Franklin Lakes, NJ, USA). Gating strategy for selected SC populations
based on negative controls is shown in Figure S1. The absolute num-
bers of circulating stem/progenitor cells/ll of PB were computed based
on (i) the percentage content of each subpopulation within the whole
leucocyte fraction and (ii) the white blood cell (WBC) count. The abso-
lute numbers of circulating stem cells were then re-calculated per millili-
tre of PB (Fig. 1) and 1 9 106 of leucocytes (Figure S2).
ImageStream analysis of circulating BMSCs
Preparation of cells for ImageStream system (ISS) analysis was per-
formed as described for classical flow cytometric methods [16]. Briefly,
the whole population of PB-derived leucocytes was subsequently
stained for morphological characterization of circulating VSELs with
fluorescent-labelled antibodies for haematopoietic lineage markers (Lin,
FITC and the set of antibodies described above for flow cytometry),
CD45 and CD34. Cells were further fixed with 4% paraformaldehyde
solution for 20 min. at room temperature and nuclei were stained with
Hoechst 33342 (2 lg/ml, Sigma-Aldrich). To identify the subpopulation
of circulating VSELs expressing markers of pluripotency, such as Oct-4
and Nanog, the whole population of PB-derived leucocytes was initially
fixed with 4% paraformaldehyde for 20 min., permeabilized with 0.1%
Triton X-100 solution for 10 min., and subsequently stained for the
nuclear transcription factors Oct-4 and Nanog with purified primary anti-
bodies against Oct-4 (clone 7F9.2; Millipore, Billerica, MA, USA) and
Nanog (clone N-17, cat. no. sc-30331; Santa Cruz Biotechnology, Santa-
Cruz, Dallas, TX, USA), respectively. Staining was performed in PBS
containing 2% FBS (Invitrogen). All samples were analysed with an Im-
ageStream imaging cytometer system (Amnis Corp., Seattle, WA, USA).
Analysis of systemic levels of complement
cascade protein cleavage fragments, SDF-1,
growth/inhibitory factors and S1P
The concentrations of SDF-1, VEGF, EGF, HGF, LIF, IGF and CC mole-
cules (C3a, C5a, C5b-9/MAC) were measured using commercially avail-
able, high-sensitivity ELISA kits (R&D Systems, Minneapolis, MN, USA
and BD Bioscience OptEIA ELISA Kits, MD, USA) according to the man-
ufacturer’s instructions. Extracellular haemoglobin (eHb) levels were
determined using spectrophotometry according to previously described
protocols [17, 18]. To measure S1P concentrations, reverse-phase
high-performance liquid chromatography (RP-HPLC) was employed
[19]. Briefly, specified volume of internal standard (S1P C17), 1 M
NaCL and methanol was added to plasma, mixed, chloroform was
added and mixture was again centrifuged. Lower organic phase was
transferred to another tube. To the non-organic phase, chloroform was
added and mixture was centrifuged. Two organic phases were com-
bined, and dried in vacuum centrifuge. Dried substance was diluted in
methanol, reactive mixture was added (o-phthaldialdehyde, methanol,
mercaptoethanol, boric acid pH 10.5), incubated and finally centrifuged.
Fig. 1 Results of cytometric analyses. Mean absolute numbers of stem/
progenitor cells circulating in peripheral blood (PB) in control individu-
als and patients with pancreatic cancer together with their statistical
comparison (means  S.D.). VSEL: very small embryonic-like stem
cells; MSC: mesenchymal stem cells; HSC: haematopoietic stem cells;
EPC: endothelial progenitor cells. *P < 0.05; **P < 0.01 (level of signif-
icance vs control individuals).
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Clear supernatant was transferred to fresh tube and analysed using
high-performance liquid chromatography. Separation was performed
using isocractic method and following separation conditions/tools were
applied: Cosmosil 5 lm C18-ARII (150 9 4.6) column; cartridge 5 lm
C18-ARII (10 9 4.6); moving phase: 10 mM K2HPO4: methanol: 1 M
TBAP (78:21.5:0.5), temperature 25°C, flow 1.0 ml/min.; fluorescence
detector (excitation: 340 nm; emission: 455 nm).
Statistical methods
To determine the distribution of the continuous variables analysed, the
Shapiro–Wilk’s test was used. For comparison of mean parameter val-
ues between examined groups, Student’s t-test was used (for normally
distributed variables). For variables that were not normally distributed,
the variable values were log transformed. If a normal distribution was
then achieved, these transformed variables were also compared using
Student’s t-test. However, if the transformation did not create a normal
distribution, the Mann–Whitney U-test was performed. Correlations
between various analysed parameters were calculated using Pearson’s
test or Spearman’s rank test, according to the normality of the distribu-
tion. Statistical analysis was performed using SPSS statistical analysis
software, and significance was defined as P < 0.05.
The study protocol was approved by the Bioethical Committee of the
Pomeranian Medical University in Szczecin, and patients provided
informed written consent for participation.
Results
Analysis of included individuals
Initial comparison of the analysed groups of recruited individuals
revealed significantly higher C-reactive protein (that still were rela-
tively within reference range) and CA19.9 levels in patients with pan-
creatic malignancy (Table 1). No other significant differences were
found between the analysed groups.
Comparison of circulating stem cells’ population
in patients with pancreatic cancer and healthy
individuals
Mean absolute numbers of various SCs populations circulating in PB
in patients with pancreatic cancer and healthy individuals are depicted
in Figure 1 and Figure S2. Our analysis demonstrated that, in com-
parison to healthy individuals, significantly higher numbers of circu-
lating VSELs and MSCs are observed in patients with pancreatic
malignancy (Fig. 1). Interestingly, numbers of other circulating stem
cell populations, that is HSCs and EPCs, do not seem to be associated
with the presence of malignancy, and levels of these BM-derived SCs
seem to be slightly, although not significantly (P = 0.07 for HSCs and
P = 0.14 for EPCs), lower than in control individuals. Unfortunately,
when we divided our cancer patients into subgroups, according to the
stage of the malignancy, we could not find any significant differences
between the subgroups in absolute numbers of circulating SCs popu-
lations (Table S1).
Potential involvement of the SDF-1, growth/
inhibitory factors, complement molecules and
S1P in mobilization of BMSCs into PB in patients
with pancreatic malignancy
Our analysis within the groups demonstrated that in generally healthy
controls, absolute numbers of circulating stem cells in PB, such as
MSCs or EPC, are associated with some anthropometric features of
examined individuals, such as BMI and age (r = 0.90; P < 0.03 and
r = 0.75; P < 0.05 respectively). Interestingly, in patients with pan-
creatic malignancy, we could not demonstrate any significant correla-
tion between analysed anthropometric parameters and absolute
numbers of circulating SCs. To establish whether observed peripheral
increase in numbers of circulating SCs is associated with systemic
changes in concentrations of well-known chemoattractant (SDF-1)
and/or growth/inhibitory factors, we measured levels of these mole-
cules in both analysed groups (Figs 2 and 3). Results demonstrated
that patients suffering from pancreatic malignancy have slightly,
although not significantly (P = 0.22), lower mean SDF-1 level than
healthy individuals. While we could establish various significant cor-
relations between absolute numbers of selected populations of circu-
lating SCs and SDF-1 levels in healthy individuals [with VSELs
(r = 0.34) and HSCs (r = 0.25), P < 0.05 for both], in patients with
pancreatic malignancy such associations were not observed, as well
as, SDF-1 levels were comparable between patients suffering from
resectable, locally advanced and metastatic disease (Table S1). In
addition, no statistically significant differences in mean levels of
VEGF, IGF and EGF were observed between healthy individuals and
cancer patients. Levels of HGF and LIF were significantly higher in
patients with pancreatic malignancy (Fig. 3). However, in our study,
only the systemic HGF levels were correlating with absolute numbers
of circulating MSCs (r = 0.72, P < 0.03), but not with VSELs
(r = 0.21, P = 0.28) in patients with malignancy.
Fig. 2Mean systemic concentrations of stromal-derived factor-1 (SDF-
1) in pancreatic cancer patients, together with their statistical compari-
son with values observed in healthy individuals (means  S.D.). SDF-1:
stromal-derived factor-1.
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We also wanted to verify whether activation of CC (C3a, C5a and
C5b-9/MAC) may be associated with increased numbers of circulating
BMSCs, that are observed in patients with pancreatic cancer. In our
study, patients suffering from pancreatic malignancy had significantly
higher systemic levels of C5a and C5b-9/MAC molecules, while C3a
concentrations were statistically comparable with those observed in
healthy individuals (Fig. 4a). Interestingly, in our study, levels of
selected examined complement fractions were strongly and signifi-
cantly correlating with absolute numbers of circulating VSELs and
MSCs in patients with pancreatic cancer (Table 2), while such tenden-
cies could not be detected in the control group. Of note, we already
reported that activation of distal part of CC and release of C5a and
C5b-9/MAC is essential for optimal egress of SCs from BM [20].
Finally, we decided to analyse whether observed C5b-9/MAC lev-
els are associated with erythrocytes’ lysis (expressed by levels of eHb
concentrations), and with increase in plasma S1P levels in healthy and
pancreatic cancer patients. However, in our study, we could not deter-
mine any significant correlation between C5b-9/MAC levels and eHb
concentration in plasma, which were comparable between both exam-
ined groups (P = 0.49; Fig. 4b). Furthermore, systemic levels of S1P
were found to be comparable between the analysed groups (P = 0.73),
as well as between patients suffering from resectable, locally advanced
and metastatic disease (Fig. 4c and Table S1). However, only in pan-
creatic cancer patients, S1P plasma concentrations were significantly
correlated with the absolute numbers of circulating PB VSELs, MSCs
and HSCs (r = 0.59, 0.63 and 0.71, respectively, P < 0.01 for all), as
well as, with systemic SDF-1 level (r = 0.85, P = 0.004).
Discussion
Recently, there has been heightened interest in the potential involve-
ment of normal SCs in the development of malignancies. Even though
in several experimental animal studies various researchers preliminar-
ily demonstrated that SCs may contribute to a development of GI can-
cers [6,7], still precise mechanisms regulating this phenomenon are
neither not known nor examined in the clinical setting. Therefore, in
this study, we have comprehensively analysed circulating numbers of
various BMSCs populations in patients suffering from pancreatic can-
cer, as well as, measured several soluble factors that are responsible
for BMSCs mobilization/retention.
In our study, we have found that pancreatic malignancy in human
beings is associated with increased numbers of systemically circulat-
ing BM-derived Lin/CD45/CD133+ and CD45/CD105+/STRO-1+
cells enriched for VSELs and MSCs, respectively, that are BMSCs
populations that possess molecular potential for trans-differentiation
into or regeneration of solid organs. We hypothesize that these circu-
lating BMSCs populations are mobilized in the course of pancreatic
cancer development to support its growth and spread. Our hypothesis
may also be supported by results of the previous studies, in which it
Fig. 3Mean systemic concentrations of growth/inhibitory factors in pan-
creatic cancer patients and healthy individuals, together with their statis-
tical comparison between the groups (means  S.D.). Statistical
analysis revealed following levels of significance for comparison of
mean values detected in healthy individuals and pancreatic cancer
patients: P = 0.34 (for VEGF), P = 0.10 (for IGF), P < 0.05 (for LIF),
P = 0.73 (for EGF) and P < 0.05 (for HGF). EGF: epidermal growth fac-
tor; HGF: hepatocyte growth factor; IGF: insulin-like growth factor; LIF:
leukaemia inhibitory factor; VEGF: vascular/endothelial growth factor.
Table 2 Coefficients of correlations between absolute numbers of
circulating stem cells’ populations and systemic levels of
complement anaphylatoxins measured in patients with pancreatic
cancer
Stem cells population/parameter C3a C5a MAC
Pancreatic cancer patients
VSEL 0.70# 0.83* 0.75#
MSC NS 0.91* 0.67#
HSC NS NS NS
EPC NS NS NS
P: level of significance; NS: not significant; VSEL: very small embry-
onic-like stem cells; MSC: mesenchymal stem cells; HSC: haematopoi-
etic stem cells; EPC: endothelial progenitor cells; MAC: membrane
attack complex (C5b-9) of the complement system.
#P < 0.05.
*P < 0.005.
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was demonstrated that BMSCs migrate to murine pancreatic tissue
for promotion of its regeneration, as well as, human pancreatic
tumours are mainly created by cancer SCs possessing high expres-
sion of CD133 antigen and embryonic markers such as Oct-4 [21–
23]. Interestingly, these markers are expressed by the population of
circulating BM-derived VSELs examined in our study. Furthermore, in
our study, we observed somehow ‘selective’ egress/mobilization of
BMSCs into PB – as only SCs populations that participate in solid
organ/tissues regeneration were mobilized. In contrast, HSCs or EPCs
did not seem to become mobilized in our patients during development
of pancreatic malignancy.
Moreover, our study also demonstrated that egress of BMSCs in
patients with pancreatic cancer seems to be executed in an SDF-1-
independent manner. While in several studies, it has been reported
that during development of pancreatic cancer the expression of SDF-
1 increases within pancreatic tissue [24, 25], results of our study
demonstrate that SDF-1 does not seem to be associated with intensi-
fied peripheral trafficking of BMSCs in patients with pancreatic cancer
and its systemic concentrations are comparable to those observed in
healthy individuals. Similar results have also been recently observed
by Vizio and colleagues [26]. This discrepancy may be explained by
the fact of enhanced activity of SDF-1 degrading proteolytic enzymes
in plasma (such as matrix metalloproteinase-9) that is observed in
majority of patients [27]. In contrast to plasma SDF-1 level, we
noticed strong associations between CC cleavage fragments and
increased BMSCs trafficking. To support this, systemic levels of C5a
and C5b-9/MAC were not only elevated, but also strongly correlated
with the increased absolute numbers of circulating BMSCs in patients
with pancreatic cancer. Our results are therefore in agreement with
some previous animal studies, which highlighted crucial involvement
of the complement cascade in promotion of BMSCs egress from the
BM environment [13]. In addition, our findings also seem to indirectly
support and translate previous experimental observations that
selected complement anaphylatoxins are likely to possess strong
chemoattractive properties for systemic migration of SCs during
development of malignancy in human beings [28].
Finally, even though it has been reported that S1P is a major
chemoattractant responsible for egress of HSCs from the BM, and
reported that its levels following HSCs mobilization increase in experi-
mental animals [13, 14], in our clinical studies such drastic changes
in systemic S1P levels in patients with pancreatic cancer were not
observed. This suggests that S1P may not play a crucial role in
egress of non-HSCs (MSCs and VSELs) from BM into PB in patients
with growing pancreatic tumour. On the other hand, we and others
have demonstrated that systemic increase in S1P levels is not essen-
tial for BMSCs mobilization in patients, as basal S1P concentrations
are already sufficient to facilitate BMSCs egress from the BM when
retentive factors are suppressed [13, 29]. Nevertheless, further stud-
ies are undoubtedly needed to clarify the exact nature of this associa-
tion between BMSCs mobilization and S1P activity during
development of pancreatic cancer in human beings.
We are aware that we have described herein an interesting phe-
nomenon and further studies are needed to explain what is its clini-
cal/pathological significance. It would be interesting to investigate if
similar phenomenon also occurs in other types of gastrointestinal
malignancies, as well as to address a basic issue – what is the role of
these SCs mobilized into circulation during pancreatic cancer devel-
opment. Do they contribute to expansion of growing tumour by pro-
viding vasculature and stroma or just it is a kind of overall response
of organism to tissue organ injury and hypoxic microenvironment of
expanding tumour [12].
In summary, our study demonstrated that in patients with pancreatic
cancer, intensified peripheral trafficking of BMSCs occurs. This phenome-
non does not seem to be caused by systemic SDF-1 concentrations, but
rather is associated with increased levels of complement molecules




Fig. 4Mean concentrations of examined complement anaphylatoxins/
molecules (a), relative eHb values# (b), and S1P (c) in pancreatic can-
cer patients and healthy individuals, together with their statistical com-
parison between analysed groups (means  S.D.). MAC: membrane
attack complex; eHb: extracellular haemoglobin; S1P: sphingosine-1-
phosphate. *P < 0.05; **P < 0.005 (level of significance vs control
individuals). # values calculated as a coefficient derived from a formula:
eHb = direct eHb level/plasma Hb level.
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significant associations between systemic HGF, S1P levels and
enhanced egress of BMSCs in patients with pancreatic cancer.
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